The efficacy of tocilizumab in a patient with pulmonary arterial hypertension associated with Castleman’s disease
- 31 July 2010
- journal article
- case report
- Published by Springer Nature in Heart and Vessels
- Vol. 25 (5) , 444-447
Abstract
Castleman’s disease is a highly heterogeneous clinical-pathological entity that belongs to the lymphoproliferative disorders and is associated with pulmonary arterial hypertension (PAH) in some patients. It is linked to excessive immune stimulation by interleukin-6 (IL-6), which is also involved in the pathogenesis of PAH. A 31-year-old woman with Castleman’s disease demonstrated PAH characterized by severe right heart failure. Since she was resistant to various conventional therapies including steroids, prostacyclins, bosentan, and sildenafil, tocilizumab (anti-IL-6 receptor antibody) therapy was started. Her clinical course was followed for 6 months, with significant improvement without any adverse effect. This is the first reported case of use of tocilizumab in addition to steroids and conventional PAH therapy in a patient with PAH associated with Castleman’s disease.Keywords
This publication has 21 references indexed in Scilit:
- Interleukin-6 Overexpression Induces Pulmonary HypertensionCirculation Research, 2009
- Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman diseaseBlood, 2008
- Atorvastatin induces associated reductions in platelet P-selectin, oxidized low-density lipoprotein, and interleukin-6 in patients with coronary artery diseasesHeart and Vessels, 2008
- Successful treatment of a patient with takayasu arteritis using a humanized anti–interleukin‐6 receptor antibodyArthritis & Rheumatism, 2008
- Interleukin-10 Expression Mediated by an Adeno-Associated Virus Vector Prevents Monocrotaline-Induced Pulmonary Arterial Hypertension in RatsCirculation Research, 2007
- Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's diseaseEuropean Respiratory Journal, 2005
- Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman diseaseBlood, 2005
- Treatment of rheumatoid arthritis with humanized anti–interleukin‐6 receptor antibody: A multicenter, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2004
- Clinical classification of pulmonary hypertensionJACC, 2004
- Alleviation of Systemic Manifestations of Castleman's Disease by Monoclonal Anti-Interleukin-6 AntibodyNew England Journal of Medicine, 1994